This information was originally presented at the NCCN 21^st Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida, from March 31 – April 2, 2016.

The 2015 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of six webinars on the topics of melanoma, biomarkers, management of cancer in older patients with comorbidities, managing symptoms and reducing complications, and two sessions on less common and complex canc

The 2015 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of six webinars on the topics of melanoma, biomarkers, management of cancer in older patients with comorbidities, managing symptoms and reducing complications, and two sessions on less common and complex canc

Gastric cancer is a leading cause of cancer death and is associated with poor prognosis. The treatment of advanced gastric cancer is changing with the development of novel agents.

Join Jaffer Ajani, MD and Brian Badgwell, MD as they present their multidisciplinary expertise on a range of cases pertaining to gastric cancer.

Join Jaffer Ajani, MD and Brian Badgwell, MD as they present their multidisciplinary expertise on a range of cases pertaining to gastric cancer.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

This symposium has been designed to bring up-to-date scientific information to clinicians involved in the care of patients with thoracic malignancies, including Lung Cancer, Mesothelioma, and Esophageal Cancer.

Carcinoma of the esophagus and gastroesophageal junction tumors presenting with locoregional disease are potentially curable, although the cure rate is modest.

Although T2,N0,M0 esophageal adenocarcinoma is grouped with other locoregional disease by NCCN, no consensus exists about how it should be treated. One of the inherent complexities of treating T2,N0,M0 esophageal adenocarcinoma is the inaccuracy of the clinical staging.